Back to top
more

Immunic (IMUX)

(Delayed Data from NSDQ)

$1.22 USD

1.22
230,465

-0.04 (-3.17%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.22 0.00 (0.00%) 5:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

by Zacks Equity Research

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Immunic (IMUX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails

by Zacks Equity Research

Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.

Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

by Zacks Equity Research

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

Why Immunic (IMUX) Stock Might be a Great Pick

by Zacks Equity Research

Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    Immunic Gets FDA Allowance for Phase II Coronavirus Study

    by Zacks Equity Research

    Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.

    Sweta Killa headshot

    High-Beta ETFs & Stocks to Tap the Soaring Stock Market

    by Sweta Killa

    While every corner of the market is enjoying this ascent, high-beta ETFs and stocks seem a perfect bet at present.

    Corporate News for May 15, 2020

    by Zacks Equity Research

    Companies In The News Are: APDN, CSCO, IMUX, VRTU